Why One Color Vision Test Is Never Enough
Approximately 300 million people worldwide live with inherited color vision deficiency (CVD), yet many are not diagnosed until adolescence or adulthood. The reason is straightforward: most clinics rely solely on the Ishihara test for color vision screening. While the Ishihara is effective at catching red-green defects, it cannot detect tritan (blue-yellow) deficiencies and offers no severity grading whatsoever.
A more complete approach uses three tests in concert: the Ishihara for rapid initial screening, the Hardy-Rand-Rittler (HRR) for classification and tritan detection, and the Farnsworth D-15 for severity grading. This article breaks down when and why to use each test so you can build a clinical workflow based on evidence, not habit.
Understanding the Three Main Color Vision Tests
Color vision tests fall into two broad categories. Pseudoisochromatic plate tests, including the Ishihara and HRR, use colored dot patterns that are visible or invisible depending on a patient's color perception. Hue arrangement tests, like the Farnsworth D-15, ask patients to sort colored caps in sequential order.
Each test answers a different clinical question. The Ishihara asks, "Is a red-green defect present?" The HRR asks, "What type and how severe?" The D-15 asks, "Does this defect have functional consequences?" The anomaloscope remains the gold standard for definitive CVD classification, but its cost and the need for a trained examiner make it impractical for routine use. These three tests form the realistic clinical toolkit.
The Ishihara Test: Strengths, Limitations, and Best Use Cases
The Ishihara test uses pseudoisochromatic plates specifically designed to detect protan (red) and deutan (green) deficiencies. It is fast, familiar, and requires minimal training to administer, which explains its dominance in primary care and school-based settings.
However, the Ishihara has two critical blind spots. First, it cannot detect tritan (blue-yellow) defects at all. Second, it provides no grading of defect severity. A patient who fails the Ishihara could have a mild anomaly with little functional impact or a severe dichromacy, and the test alone cannot distinguish between the two.
Clinical data reinforces these limitations. In a comparative study of 150 subjects, the Ishihara identified only 7 individuals with congenital red-green deficiency, while the HRR 4th Edition identified 12 in the same cohort, including cases the Ishihara missed entirely.
Best use case: rapid initial screening in high-volume environments such as school vision screenings or general optometry intake, where the primary goal is flagging red-green defects for further evaluation. For context, New York State mandates color vision testing in school screenings, though an abnormal result alone does not trigger a mandatory follow-up referral.
One often-overlooked caveat: reduced visual acuity can produce false positives on Ishihara plates. If a patient struggles to resolve the dot patterns due to uncorrected refractive error or other causes, the result may not reflect actual CVD. Always confirm adequate acuity before interpreting Ishihara results.
The HRR 4th Edition: The Most Clinically Complete Plate Test
The HRR stands apart as the only widely used plate test capable of detecting all three types of CVD: protan, deutan, and tritan defects. This makes it significantly more versatile than the Ishihara for both congenital and acquired color vision assessment.
The Richmond HRR 4th Edition, re-engineered in 2002, addressed shortcomings in earlier versions with improved colorimetric design and tritan plates aligned with actual confusion lines. The result is a test with exceptional diagnostic performance: 100% sensitivity using a two-error fail criterion, 100% specificity at a three-error criterion, and 96.67% overall diagnostic accuracy in a study of 150 subjects aged 15 to 25.
Beyond screening, the HRR classifies defects as mild, moderate, or severe. This severity grading is a feature the Ishihara entirely lacks, and it directly informs clinical decision-making about whether further testing or occupational counseling is warranted.
The HRR also performs well in acquired CVD contexts. For detecting dyschromatopsia in optic neuropathy (such as non-arteritic anterior ischemic optic neuropathy), the HRR achieved 86% sensitivity, 72% specificity, and an area under the curve (AUC) of 0.87. These figures support its use beyond congenital screening.
Occupational relevance is another strength. The HRR correctly classifies protan and deutan defects in 86% of cases, with only 3% incorrectly classified. For aviation, transport, and safety-critical roles where the type of defect matters as much as its presence, this classification accuracy is essential for guiding referral decisions.
The Farnsworth D-15: Severity Grading and Occupational Pass/Fail
The Farnsworth D-15 takes a fundamentally different approach. Patients arrange 15 colored caps (plus one fixed reference cap) in sequential hue order, based on the Munsell color system. The pattern of errors reveals both the type and functional severity of a color vision defect.
The D-15 is not a first-line screening tool. It is designed to identify moderate-to-severe CVD in patients who have already failed a plate test. This is where its complementary relationship with the HRR becomes clear: subjects classified as "mild" by the HRR typically pass the D-15, while approximately 40% of those classified as "medium" by the HRR fail it. The D-15 effectively answers the question, "Is this defect severe enough to matter functionally?"
For acquired CVD, the D-15 offers a valuable serial monitoring capability. In patients with glaucoma or diabetic retinopathy, worsening D-15 severity grades over time can indicate disease progression, making the test a practical addition to chronic disease management workflows.
Repeatability data supports this use: the D-15 has a kappa coefficient of 0.84, indicating good (though not perfect) test-retest reliability. This is adequate for occupational screening and serial monitoring, though clinicians should be aware of this margin when interpreting borderline results.
It is worth distinguishing the standard (saturated) D-15 from the Lanthony desaturated D-15. The desaturated version uses paler caps and is more sensitive for detecting mild deficiencies that the standard D-15 would miss. Choose the version that matches your clinical question.
A 2024 study confirmed that D-15 testing can be reliably performed on digital screens, even in desaturated format. This finding improves accessibility for remote and resource-limited settings, though physical test kits remain the reference standard for clinical and occupational decisions.
Choosing the Right Test: A Clinical Decision Framework
Rather than defaulting to a single test, consider a structured three-step workflow:
- Step 1: Ishihara for rapid screening. Use it as the initial gate in general intake or school-based settings. A pass rules out significant red-green defects. A fail moves the patient to Step 2.
- Step 2: HRR for classification. If the Ishihara is failed, or if a tritan defect is suspected (common in acquired conditions), administer the HRR 4th Edition. It will identify the defect type (protan, deutan, or tritan) and grade severity as mild, moderate, or severe.
- Step 3: D-15 for functional severity and occupational decisions. For patients with moderate or severe HRR results, the D-15 confirms functional impact and provides the pass/fail determination often required for aviation, transport, military, and electrical trade certifications.
Pediatric and School Screening
The 2025 update from the American Academy of Optometry recommends CVD screening for children with suspected color vision deficiency or a reported family history. Given that global CVD prevalence reaches 4.38% in males, systematic screening catches cases that would otherwise go unrecognized for years.
Acquired CVD Monitoring
For patients with glaucoma, diabetic retinopathy, or optic neuropathy, pair the HRR and D-15 at regular intervals. The HRR detects new or worsening tritan defects (often the earliest sign of acquired damage), while serial D-15 results track functional progression over time.
Occupational Screening
The D-15 is frequently the definitive occupational pass/fail tool, while the HRR's classification of protan versus deutan defects informs whether a specific occupational restriction applies. Use both when the stakes are high.
A Note on Lighting
Standardized illumination is required for accurate results on both the HRR and D-15. Inconsistent clinic lighting, particularly fluorescent overhead fixtures with poor color rendering, is a common and preventable source of diagnostic error. Verify your testing environment meets recommended illumination standards before drawing clinical conclusions.
Putting It Into Practice
No single color vision test covers every clinical scenario. The Ishihara screens quickly but misses tritan defects and severity. The HRR classifies all three defect types with strong diagnostic accuracy. The D-15 grades functional severity and supports occupational and serial monitoring decisions. Together, they close the gaps that any one test leaves open.
With a global CVD prevalence of 4.38% in males and many patients unaware of their condition until well into adulthood, systematic screening with the right tools is a meaningful clinical contribution. Emerging digital options, including AI-powered apps and validated digital D-15 platforms, are promising complementary tools, but they have not yet replaced the reliability of physical, clinical-grade test batteries.
At Good-Lite, we have been supporting eye care professionals with trusted vision testing solutions since 1930. If your current protocol relies on a single screening test, this is a good time to review your color vision testing workflow and consider whether a three-test approach better serves your patients and your practice.
